Small Swedish biotech companies often have a business model of selling their research and drug candidates to larger pharmaceutical companies through licensing – a strategy that has become more important as the interest from investors seems to have cooled somewhat in recent years.
The purpose is to bring in capital, get help to finance the clinical trials in the later phases, bring knowledge and experience into the project, and handle the demanding job of commercialisation once the product is approved.
BREAKING